as 05-14-2025 9:51am EST
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Founded: | 1987 | Country: | United States |
Employees: | N/A | City: | WATERTOWN |
Market Cap: | 390.0M | IPO Year: | 2005 |
Target Price: | $24.00 | AVG Volume (30 days): | 610.5K |
Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.43 | EPS Growth: | N/A |
52 Week Low/High: | $3.91 - $21.26 | Next Earning Date: | 05-07-2025 |
Revenue: | $56,042,000 | Revenue Growth: | 12.04% |
Revenue Growth (this year): | -42.04% | Revenue Growth (next year): | -42.41% |
EYPT Breaking Stock News: Dive into EYPT Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Simply Wall St.
3 days ago
Simply Wall St.
4 days ago
Zacks
7 days ago
Zacks
7 days ago
Associated Press Finance
7 days ago
GlobeNewswire
7 days ago
GlobeNewswire
14 days ago
The information presented on this page, "EYPT EyePoint Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.